anticoagulation
play

Anticoagulation Laurel Newman Quality implementation Manager Primary Care Clinical Program Objectives 1. Clinical program strategy for 2017 2. Correctly prescribe warfarin in iCentra 3. Utilization of the Monthly Patient Watch List 4.

0 downloads 6 Views 575 KB Size Report
  1. Anticoagulation Laurel Newman Quality implementation Manager Primary Care Clinical Program

  2. Objectives 1. Clinical program strategy for 2017 2. Correctly prescribe warfarin in iCentra 3. Utilization of the Monthly Patient Watch List 4. Anticoagulation webpage

  3. Medical Group Leadership Responsible for operations to provide safe and effective management of patients who require anticoagulation. The Ask: Support Anticoagulation best practice philosophy and operations • Assure physicians and staff participate in iCentra “Go Live” training • Allow for clinical staff to enroll patients into the protocol prior to “Go Live” • Define a workflow for each clinic (POC vs lab) • Identify a physician leader and clinical staff leader in each clinic and have • them attend clinical program quarterly meetings

  4. Our Proposal Maintenance (On iCentra and using the protocol) • Laurel will hold quarterly meetings with: • The appointed PPC anticoagulation lead • Staff anticoagulation lead • John Bracken’s team • Clinical Quality Region Lead • iCentra ambulatory workflow leads • John Bracken’s team will train new employees

  5. Models Each Provider manages their own patients • Point of Care in the clinic (preferred method) • Utilization of lab services Region Anticoagulation Clinic managed by APC or pharmacy services

  6. Prescribing Warfarin in iCentra Pre-populated Warfarin Orders can be added to your favorites.

  7. Prescribing Warfarin in iCentra Weekly doses will be managed in the Anticoagulation workflow, not the medication list.

  8. Review your list to determine: Is this patient still taking warfarin? If not, remove the patient • from the protocol. If they are taking warfarin, does the indication warrant • indefinite therapy or perhaps are they a candidate for cessation (e.g. surgically provoked DVT/PE). If they require continued anticoagulation therapy and are • having a difficult time achieving a safe time in therapeutic range (TTR), can modifiable barriers to optimal anticoagulation be identified? Seeing patients with poor INR control more frequently is • associated with improving TTR. Among patients on warfarin with suboptimal anticoagulation • control, might transition to a DOAC be a consideration? A dedicated visit to address anticoagulation therapy can • improve quality of anticoagulation management.

  9. Updated Anticoagulation Web Page

Recommend Documents


approaches to educating patients on oral anticoagulation
Approaches to Educating Patients on

Approaches to Educating Patients on Oral Anticoagulation Amy A. Levesque

managing gt 8 inr s in an anticoagulation clinic sean o
Managing >8 INRs in an

Managing >8 INRs in an Anticoagulation clinic. Sean OBrien

managing 8 inr s in an anticoagulation clinic sean o
Managing >8 INRs in an

Managing >8 INRs in an Anticoagulation clinic. Sean OBrien

pediatric anticoagulation
Pediatric Anticoagulation Discuss

Pharmacist Objectives Compare and contrast differences between adult and

the pitfalls of any qualified provider aqp joanne malpass
The pitfalls of Any Qualified Provider

The pitfalls of Any Qualified Provider (AQP) Joanne Malpass, Anticoagulation

inpatient anticoagulation management services to improve
Inpatient Anticoagulation Management

Inpatient Anticoagulation Management Services to Improve Transitions of Care

anticoagulation therapy
Anticoagulation Therapy Your key

Latest Frontiers in Anticoagulation Therapy Your key questions for 2018

anticoagulation therapy
Anticoagulation Therapy Your key

Latest Frontiers in Anticoagulation Therapy Your key questions for 2018

an inpatient perspective on the joint commission national
An Inpatient Perspective on the Joint

An Inpatient Perspective on the Joint Commission National Patient Safety

blackpool hospital trust
Blackpool Hospital Trust Sean OBrien

ADAS Referral Site Anticoagulation Dosing Advisory Service Blackpool Hospital

new anticoagulants when and why should i use them
New Anticoagulants: When and Why Should

Winship Cancer Institute of Emory University New Anticoagulants: When and Why

improving stroke prevention in patients with atrial
Improving Stroke Prevention in

Improving Stroke Prevention in Patients With Atrial Fibrillation

application for approval to manufacture esn containing
Application for approval to manufacture

Application for approval to manufacture ESN containing sodium nitrite and a

dose response assessments guidance experience expectations
Dose Response Assessments: Guidance,

Dose Response Assessments: Guidance, Experience, Expectations Vikram Sinha,

how technology assessment by hospitals differs from
How Technology Assessment by Hospitals

How Technology Assessment by Hospitals Differs from Technology Assessment by

inhibition under flow
inhibition under flow SHANNON BRIDE

A mathematical model of surface-mediated enzyme inhibition under flow

updates in thrombosis
Updates in Thrombosis Dr. Ali Y.

Updates in Thrombosis Dr. Ali Y. Al-Muhaini MBBch FRCP(C) Chairman of the

showcasing
Showcasing health innovation Dr Samus

Showcasing health innovation Dr Samus ONeill Chair AHSN Network, CEO AHSN

drug spending of healthcare spending
Drug Spending % of Healthcare Spending

Drug Spending % of Healthcare Spending DRUG SPENDING % OF HEALTHCARE SPENDING

expanded mandate medicines patent pool for essential
EXPANDED MANDATE: MEDICINES PATENT

EXPANDED MANDATE: MEDICINES PATENT POOL FOR ESSENTIAL MEDICINES KEY FINDINGS

atrial fibrillation reducing the risk of stroke
Atrial fibrillation Reducing The Risk

Atrial fibrillation Reducing The Risk of Stroke Bjrn Fredriksson Arrhythmia

sandy bartlett phd pharmd bcps associate professor
Sandy Bartlett, PhD, PharmD, BCPS

Sandy Bartlett, PhD, PharmD, BCPS Associate Professor | Department of Pharmacy